Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Down 5.39%
As of Monday, September 14, Orchestra BioMed Holdings, Inc.’s OBIO share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. OBIO
$5.70
0.06
1.06%
October 15, 2026 12:29:19 PM
EST
Volume: 84,873
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Commentary & Analysis
Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.57%
As of Friday, September 11, Orchestra BioMed Holdings, Inc.’s OBIO share price has surged by 7.57%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 6.97%
As of Thursday, September 10, Orchestra BioMed Holdings, Inc.’s OBIO share price has surged by 6.97%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 10.81%
As of Tuesday, August 18, Orchestra BioMed Holdings, Inc.’s OBIO share price has surged by 10.81%, which has investors questioning if this is right time to sell.Michael Rose
Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 11.55%
As of Tuesday, August 18, Orchestra BioMed Holdings, Inc.’s OBIO share price has surged by 11.55%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | OBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $339.0 | $376.8 | 34% |
|
| Shares Out (Mil) | 63.8 | 40.7 | 53% |
|
| Institutional Ownership | 86.7% | 83.2% | 54% |
|
| Float (Mil) | 33.0 | 35.1 | 38% |
|
| Beta | 0.50 | 0.85 | 28% |
|
| Avg Daily Volume (000s) | 269 | 314 | 49% |
|
| Price Change (52-week) |
76.8% | 61.6% | 91% |
|
| Growth | OBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 42.5% | 11.8% | 94% |
|
| Net Income (5yr) | (19.8%) | (5.5%) | 20% |
|
| EPS (5yr) | 36.3% | 10.4% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (45.4%) | (15.5%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.402) | ($1.517) | ($1.510) | |
| Month Ago EPS | ($0.408) | ($1.523) | ($1.516) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.384) | ($1.496) | ($1.458) | |
| Year/Year Chg | 6.6% | 36.8% | (14.2%) | |
| Financials | OBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $32 | $128 | 16% |
|
| Net Income (TTM) (Mil) | ($59) | ($9) | 15% |
|
| EPS (TTM) | ($1.000) | ($0.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($58) | ($2) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $1 | 47% |
|
| Long-Term Debt (Q1) (Mil) | $70 | $26 | 42% |
|
| Enterprise Value (Q1) (Mil) | $236 | $409 | 27% |
|
| Valuation | OBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.63 | 2.49 | 95% |
|
| P/E | na | 25.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | OBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 99.5% | 59.0% | 96% |
|
| Net Margin | (184.6%) | (6.9%) | 5% |
|
| ROA | (74.5%) | (12.2%) | 8% |
|
| ROE | (601.8%) | (10.7%) | 1% |
|
| Liabilities to Assets | 74.6% | 47.2% | 70% |
|
| F-Score | 5 | 4 | 50% |
|
Orchestra BioMed Holdings, Inc. did not pass any screens on 10/14/2026.
